Ardelyx Licenses NHE3 Inhibitor Programme to AstraZeneca in its First Major Deal
By Heather Cartwright
Pharma Deals Review: Vol 2012 Issue 11 (Table of Contents)
Published: 2 Nov-2012
DOI: 10.3833/pdr.v2012.i11.1827 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
AstraZeneca has licensed global rights to Ardelyx’ NHE3 (sodium–hydrogen antiporter 3) inhibitor programme, including its lead product RDX5791, in a deal potentially worth US$870 M...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS